Cardiovascular Disease Risk in Survivors of Breast Cancer

AbstractPurpose of reviewEarly detection and improved treatment in breast cancer have resulted in an increased number of survivors. Cardiovascular disease now remains an important cause for morbidity and mortality in this population. There is a growing gap in the knowledge about the optimal long-term cardiovascular management of this population.FindingsBreast cancer and cardiovascular disease share a number of common risk factors. Different breast cancer treatment modalities, including anthracyclines, radiation, and hormonal therapy, can act in synergy with preexisting and/or new cardiovascular risk factors to result in significant cardiovascular disease.SummaryWe summarize the recent evidence about cardiovascular effects of breast cancer therapy and recommendations for their diagnosis and management during the cancer treatment continuum into survivorship. We also present current research initiatives and how they inform clinical care.
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research

Related Links:

CONCLUSION: QoL of Egyptian females with BC was influenced by several factors like age, marital status, occupation, smoking, residence, comorbidities, symptoms, grade, chemotherapy, radiation, and recurrence. PMID: 31653162 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
AbstractDespite the efforts that have been made in the field of breast cancer therapy, it is a leading cause of cancer death in women and a major health problem. The current treatments combine several strategies (surgery, radiotherapy, immunotherapy, hormone therapy, and chemotherapy) depending on cancer subtype and tumour stage. The use of chemotherapy is required in certain circumstances, like before or after surgery or in advanced stages of the disease. Chemotherapeutic regimens that include anthracyclines (e.g. doxorubicin), taxanes (e.g. paclitaxel), 5-fluorouracil and/or cyclophosphamide show, in general, a high toxi...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on literature review, about osteoporosis prevention and treatment in these patients. The following scientific societies contributed to the work : Société Française de Rhumatologie (SFR), Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO), Groupe Européen d'Etudes des Métastases Osseuses (GEMO), Association Francophone pour les Soins Oncologiques de Support (AFSOS), Société Française de Sénologie et de Pathologie M...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research
Hepatoma-Derived Growth Factor and DDX5 Promote Carcinogenesis and Progression of Endometrial Cancer by Activating β-Catenin Chunhua Liu1†, Lijing Wang1†, Qingping Jiang2†, Junyi Zhang3†, Litong Zhu1, Li Lin1, Huiping Jiang1, Dan Lin1, Yanyi Xiao1, Weiyi Fang1,3 and Suiqun Guo1* 1Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China 2Department of Pathology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China 3Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guang...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this study, we have developed new classes of SERDs that contain the OBHSA core structure and different side chains, e.g., basic side chains, long alkyl acid side chains, and glycerol ether side chains, to simply mimic the degrons of proteolysis targeting chimera (PROTAC) and then investigated the structure-activity relationships of these PROTAC-like hybrid compounds. These novel SERDs could effectively inhibit MCF-7 cell proliferation and demonstrated good ERα degradation efficacy. Among the SERDs, compounds 17d, 17e and 17g containing a basic side chain with a N-trifluoroethyl substituent and a para methoxyl gr...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
Publication date: Available online 19 March 2019Source: European Journal of Integrative MedicineAuthor(s): Shiao Li Oei, Anja Thronicke, Matthias Kröz, Cornelia Herbstreit, Friedemann SchadAbstractIntroductionViscum album L. extracts (VA) are frequently used in integrative oncology to enhance health-related quality of life. As a central aspect of well-being is associated with feeling warm or cold the internal coherence scale (ICS) questionnaire including the thermo coherence measurement was utilized.MethodsA prospective observational longitudinal cohort study was conducted, using data from the Network Oncology clinica...
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Researchers from the University of Wisconsin School of Medicine and Public Health have discovered a new way to measure the efficacy or failure of hormone therapy for breast cancer patients. A study detailing the findings was published in the February issue of The Journal of Nuclear Medicine. The findings showed that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) has been found to successfully measure changes in progesterone receptor (PR) levels resulting from a short-course estrogen treatment, also known as an estradiol challenge. Estrogen-receptor (ER)-positive breast cancer is...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
(Society of Nuclear Medicine and Molecular Imaging) Physicians may soon have a new way to measure the efficacy of hormone therapy for breast cancer patients, according to research published in the February issue of The Journal of Nuclear Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health&Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future r...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
(American Association for Cancer Research) An evaluation of breast cancer patients enrolled in Medicaid showed that states that expanded Medicaid during 2011 to 2017 had a 27 percent increase in prescriptions for hormonal therapy medications compared to states that did not expand Medicaid during the same period.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Heart | Hormonal Therapy | Hormones